Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented placenta expanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company’s PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products. It also develops PLX-PAD cells, which are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases, as well as for hematological and women’s health diseases; and PLX-R18 cells for the treatment of bone marrow failure from various causes and acute radiation syndrome. In addition, the company is involved in the development and commercialization of a PLX cells for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation; commercialization agreement with CHA Biotech Co. Ltd.; and collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapy. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.